PO.TB10.15 · 肿瘤生物学
脂质纳米探针磁珠实现高纯度血浆 EV 分离，用于广谱癌症生物标志物检测
Lipid nanoprobe magnetic beads enable high-purity plasma EV isolation for broad-spectrum cancer biomarker detection
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言：细胞外囊泡（EVs）携带肿瘤源性生物分子，是基于液体活检的癌症检测的一个有前景的来源。许多近期研究已从血浆 EV 中揭示了关键生物标志物，为胰腺癌、卵巢癌及其他难以诊断的癌症建立了潜在的诊断靶点1。与循环游离 DNA（cfDNA）或可溶性蛋白不同，EVs 由存活的肿瘤细胞主动分泌，将蛋白质、核酸和脂质包裹在保护性双层膜内，从而保持分子完整性。这种稳定性和细胞特异性使 EVs 成为微创疾病监测的理想选择。然而，血浆 EV 分离仍受到大量蛋白污染物的挑战，这些污染物会影响下游分子分析。一种简便、高纯度、可自动化兼容的分离方法对于改善基于 EV 的生物标志物分析至关重要，尤其是对异质性血液来源样本。
方法：一种基于脂质纳米探针（LNP）的磁珠系统（Captis Diagnostics Inc）经过优化，可快速、高特异性地富集血浆 EVs2。富集后的 EVs 通过货物 DNA、RNA 和核心四跨膜蛋白丰度进行评估，并与富集前样本进行比较。通过免疫测定确认了白蛋白和脂蛋白污染物的清除。将回收效率和纯度指标与领先的商用 EV 分离试剂进行了基准比较。为评估广谱生物标志物兼容性，将来自多种癌症细胞系的 EVs 加入健康血浆中，并使用 LNP 磁珠进行分离。富集后的 EVs 使用 OriGene 多重免疫测定组套进行分析，该组套涵盖癌症相关蛋白类别，包括粘附分子、致癌受体和免疫调节因子。这些标志物代表了关键的肿瘤特征，如侵袭、迁移、免疫逃逸和治疗耐药——通常存在于实体瘤的 EVs 中。
结果：基于 LNP 的 EV 富集实现了极高的 EV 回收率（>85%），与基准试剂相比，白蛋白和脂蛋白的携带残留大幅减少。免疫测定组套在多种细胞系来源的 EVs 中稳健地检测到关键的癌症相关生物标志物。结果显示了强烈的 EV 特异性信号以及非特异性背景的显著降低。这些发现表明，LNP 分离提供了卓越的纯度以及与下游定量分析的稳健兼容性。
结论：LNP 介导的 EV 富集提供了一个快速、高纯度且样本高效的平台，可直接从血浆中捕获癌症源性生物标志物。当与组学测定相结合时，该方法可实现对肿瘤源性 EVs 的广泛表型表征，并支持微创诊断和治疗监测策略的开发。
查看英文原文 English abstract
Introduction : Extracellular Vesicles (EVs) carry tumor-derived biomolecules and represent a promising source for liquid biopsy-based cancer detection. Many recent studies have revealed critical biomarkers from plasma EV, establish potential diagnostic targets for pancreatic cancers, ovarian cancers and other hard-to-diagnose cancers 1 . Unlike circulating free DNA (cfDNA) or soluble proteins, EVs are actively secreted by viable tumor cells and encapsulate proteins, nucleic acids, and lipids within a protective bilayer that preserves molecular integrity. This stability and cell specificity make EVs ideal for minimally invasive disease monitoring. However, plasma EV isolation remains challenged by abundant protein contaminants that compromise downstream molecular analysis. A simple, high-purity, automation-compatible isolation method is essential to improve EV-based biomarker profiling, particularly from heterogeneous blood derived samples.
Methods : A lipid nanoprobe (LNP)-based magnetic bead system (Captis Diagnostics Inc) was optimized for rapid, high-specificity enrichment of plasma EVs 2 . EVs post enrichment were assessed by cargo DNA, RNA and core tetraspanin abundance compared with pre-enrichment samples. Depletion of albumin and lipoprotein contaminants were confirmed by immunoassays. Comparative recovery efficiency and purity metrics were benchmarked against leading commercial EV isolation reagents. To assess broad biomarker compatibility, EVs from multiple cancer cell lines were spiked into healthy plasma and isolated using LNP beads. Enriched EVs were analyzed using OriGene multiplexed immunoassay panels covering cancer-relevant protein classes, including adhesion molecules, oncogenic receptors, and immune-modulatory factors. These markers represent key tumor hallmarks such as invasion, migration, immune evasion, and therapeutic resistance-commonly represented in EVs from solid tumors.
Results : LNP-based EV enrichment achieved very high EV recovery (>85%) with substantially reduced albumin and lipoprotein carryover compared with benchmark reagents. The immunoassay panels demonstrated robust detection of key cancer-associated biomarkers across diverse cell-line-derived EVs. The results demonstrating strong EV-specific signals and substantial reduction of nonspecific background These findings indicate that LNP isolation provides superior purity and robust compatibility with downstream quantitative analyses.
Conclusion : LNP-mediated EV enrichment provides a rapid, high-purity, and sample-efficient platform for capturing cancer-derived biomarkers directly from plasma. When integrated with omic-assays, this approach enables broad phenotypic characterization of tumor-derived EVs and supports development of minimally invasive diagnostic and treatment-monitoring strategies.
利益披露 Disclosure
Q. Ma, None..
D. Kong, None..
S. Narula, None..
J. Chen, None.